Inovio Pharma (INO) Swings to Q3 Profit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
Go back to Inovio Pharma (INO) Swings to Q3 Profit
November 9, 2015 2:46 PM EST
Stifel affirms its Buy rating and $19 price target on Inovio (Nasdaq: INO) following the company's Q3 report and update issued earlier Monday.
Analyst Thomas Shrader, PhD, CFA, noted that EPS of $0.07 was flat with consensus estimates and revenue was driven by... More
November 5, 2015 9:01 AM EST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today an interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses and was well tolerated in all evaluable patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18.
The immunology results show that INO-3112 generated robust HPV16/18 specific CD8+ T cell responses and antibodies against HPV16/18 in all 10 tested patients who received all treatments. These results will be presented today and tomorrow at the 30th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer in National... More
